Clinical Trial Update: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors [Phase 1, Phase 2]

View source ↗

Summary

ImmunityBio's QUILT-3.044 trial evaluating the NANT NSCLC vaccine in patients who progressed after PD-1/PD-L1 inhibitors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NANT NSCLC vaccine (NANT NSCLC vaccine)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: WITHDRAWN